期刊文献+

大剂量异环磷酰胺治疗进展期软组织肉瘤的疗效评价 被引量:3

Effect of continuous-infusion with high-dose ifosfamide on advanced soft tissue sarcomas
下载PDF
导出
摘要 目的:评价大剂量异环磷酰胺治疗进展期软组织肉瘤的临床疗效和不良反应。方法:进展期软组织肉瘤患者24例,异环磷酰胺总量14g/m^2持续灌注24h,第1~6天行常规美斯钠(mesna)解毒和水化,28d为1个周期,共完成1~4个周期,中位周期数为3。结果:全组患者CR3例(12.5%),PR8例(33.3%),SD8例(33.3%),PD5例(20.8%),总有效率45.8%(11/24)。接受一线和二线化疗患者为5例和19例,一线化疗3例获CR或PR;二线化疗8例获CR或PR。主要毒副反应为骨髓抑制,其白细胞Ⅲ~Ⅳ度下降发生率为51.4%,其他不良反应少见。结论:大剂量异环磷酰胺是治疗进展期软组织肉瘤有效化疗方案,患者缓解率较高,毒副反应可以耐受,值得临床进一步观察。 Objective:To evaluate the efficacy and adverse reaction of continuous infusion with high-dose ifosfamide on soft tissue sarcoma (STS). Methods: Twenty four patients with advanced soft tissue sarcoma were given a 24 h continuous infusion of ifosfamide at a total dose of 14 g/mz. From d 1 to d 6 adequate mesna were given for protection and hydration. Twenty eight days were regarded as one cycle and 1-4 cycles were completed. The median cycle number was 3. Results:Three cases had com- plete remission (CR) (12.5%), 8 cases achieved partial remission (PR) (33.3%), 8 cases maintained a stable disease (SD) (33.3%), and 5 cases had progressive disease (PD) (20. 8%). The overall response rate (RR) was 45.8% (11/24). Five patients received first line chemotherapy and 3 cases achieved CR or PR. Ninteen patients received second line chemotherapy and 8 cases achieved CR or PR. The main adverse reaction was myelosupression. Neutropenia at grade Ⅲ-ⅣV occurred in 51.4% patients. Other adverse reactions were seldom observed. Conclusion:Continuous infusion of high-dose ifosfamide is effective for STS. The RR is high and the side effects can be tolerable. So its clinical effect is worthy of further observation.
出处 《肿瘤》 CAS CSCD 北大核心 2007年第1期70-72,共3页 Tumor
关键词 软组织肿瘤 化学疗法 辅助 异环磷酰胺/副作用 Soft tissue neoplasmst Chemotherapy,adjuvant Ifosfamide/adverse effects
  • 相关文献

参考文献16

  • 1NIELSEN O S,JUDSON I,VAN HOESEL Q,et al.Effect of high-dose ifosfamide in advanced soft tissue sarcomas:a multicentre phase Ⅱ study of the EORTC Soft Tissue and Bone Sarcoma Group[J].Eur J Cancer,2000,36(1):61-67.
  • 2ROBINSON M H.The management of adult soft tissue sarcomas[J].Clin Oncol,1994,6(3):183-192.
  • 3VRAA S,KELLER J,NIELSEN O S,et al.Prognostic factors in soft tissue sarcomas:the Aarhus experience[J].Eur J Cancer,1998,34(12):1876-1882.
  • 4O'BYRNE K,STEWARD W P.The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas[J].Crit Rev Oncol Hematol,1998,27(3):221-227.
  • 5VERWEIJ J,MOURIDSEN H T,NIELESSEN O S,et al.The present state of the art in chemotherapy for soft tissue sarcomas in adults:the EORTC point of view[J].Crit Rev Oncol Hematol,1995,20(3):193-201.
  • 6GARCIA-CARBONERO R,SUPKO J G,MANOLA J,et al.Phase Ⅱ and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy[J].J Clin Oncol,2004,22(8):1480-1490.
  • 7SANTORO A,TURSZ T,MOURIDSEN H,et al.Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas:a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group[J].J Clin Oncol,1995,13(7):1537-1545.
  • 8EDMONSON J H,RYAN L M,BLUM R H,et al.Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin,doxorubicin and cisplatin against advanced soft tissue sarcomas[J].J Clin Oncol,1993,11(7):1269-1275.
  • 9ANTMAN R,CROWLEY J,BALCERZAK SP,et al.An intergroup phase Ⅲ randomised study of doxorubicin and dacanbazine with or without ifosfamide and mesna in advanced softtissue and bone sarcomas[J].J Clin Oncol,1993,11 (7):1276-1285.
  • 10VAN OOSTEROM A T,MOURIDSEN H T,NEILSEN O S,et al.Results of randomized studies of the EORTC soft tissue and bone sarcoma group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients[J].Eur J Cancer,2002,38(18):2397-2406.

二级参考文献2

共引文献3

同被引文献23

  • 1李从铸,李同度.癌症恶病质的发生及治疗的实验研究[J].中国肿瘤临床,1996,23(12):885-888. 被引量:23
  • 2华绍芳,薛凤霞.未绝经妇女子宫内膜癌的临床病理特征及预后[J].天津医药,2007,35(5):341-343. 被引量:4
  • 3Piccart M J, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxe versus cisplafin - cyclophosphamide in women with advanced epithelial ovarian cancer: three- year results [J]. J Natl Cancer Inst, 2000, 92: 699-708.
  • 4McGuire WP, Hoskins W J, Brady MF, et al. Cyclophosphamide and cisplatln compare with paclitaxel and cisplatin in patients with stage Ⅲ and stage IV ovarian cancer [J]. N Engl J Med, 1996, 334: 1-6.
  • 5Ozols RF. Future directions in the treatment of ovarian cancer[J]. Semin Oncol, 2002, 29 (Suppl): 32-42.
  • 6Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg permeters squared with carbop latin in advanced ovarian cancer: a randomized triM[J]. Clin Oncol, 2004, 22 (4): 686.
  • 7Lambert HE, Rustin G J, Gregogy WM, et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian cancer[J]. Ann Oncol, 1997, 8: 327-333.
  • 8Ilson DH.Esophageal cancer: new developments in systemic therapy. Cancer Treat Rev, 2003,29(6) : 525 -532.
  • 9Ajani JA.Treatment of patients with upper gastrointestinal carcino - mas.Samin Oncal, 1997,24(Supp135) : 3572-3574.
  • 10Imran A,Neelam F,Tariq M.Incidence of cimulafing antinuclear anti- bodies in cancer patients.Indian J Med Sci ,2003,57(3 ):13-16.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部